|
11.
|
|
18 p, 2.5 MB |
Recommendations for the diagnosis and radiological follow-up of pituitary neuroendocrine tumours Recomendaciones sobre el diagnóstico y seguimiento radiológico de los tumores neuroendocrinos hipofisarios
/
Fajardo-Montañana, Carmen (Hospital Universitario de la Ribera. Departamento de Endocrinología) ;
Villar, Rocío (Complejo Hospitalario Universitario de Santiago de Compostela) ;
Gómez-Ansón, Beatriz (Institut d'Investigació Biomèdica Sant Pau) ;
Brea, Beatriz (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Mosqueira, Antonio Jesús (Complejo Hospitalario Universitario de Santiago. Departamento de Radiología) ;
Molla, Enrique (Hospital Universitario de la Ribera. Departamento de Radiología) ;
Enseñat, Joaquín (Hospital Clínic i Provincial de Barcelona. Departament de Neurocirurgia) ;
Riesgo, Pedro (Hospital Universitario de la Ribera. Departamento de Neurocirugía) ;
Cardona-Arboniés, Jorge (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Hernando, Ovidio (Centro Integral Oncológico Clara Campal. Departamento de Oncología Radioterápica)
Pituitary neuroendocrine tumours (PitNETs) constitute a heterogeneous group of tumours with a gradually increasing incidence, partly accounted for by more sensitive imaging techniques and more extensive experience in neuroradiology in this regard. [...]
2022 -  10.1016/j.endinu.2021.10.005
Endocrinología, diabetes y nutrición, Vol. 69 Núm. 9 (noviembre 2022) , p. 744-761
|
|
|
12.
|
|
25 p, 618.2 KB |
Impact of Age on the Effectiveness and Safety of Insulin Glargine 300 U/mL : Results from the REALI European Pooled Data Analysis
/
Bonadonna, Riccardo C (University of Parma) ;
Mauricio Puente, Dídac (Institut d'Investigació Biomèdica Sant Pau) ;
Müller-Wieland, Dirk (University Hospital Aachen (Alemanya)) ;
Freemantle, Nick (University College London) ;
Bigot, Gregory (IVIDATA Group) ;
Mauquoi, Celine (International Drug Development Institute (IDDI)) ;
Ciocca, Alice (Sanofi) ;
Bonnemaire, Mireille (Sanofi) ;
Gourdy, Pierre (Université de Toulouse)
Introduction: Patients aged ≥ 65 years continue to be underrepresented in clinical studies related to type 2 diabetes mellitus (T2DM). Accordingly, the REALI pooled analysis was performed to evaluate the effectiveness and safety of insulin glargine 300 U/mL (Gla-300) across different age subgroups, using data from 14 interventional and non-interventional studies. [...]
2021 - 10.1007/s13300-021-01030-0
Diabetes Therapy, Vol. 12 Núm. 4 (april 2021) , p. 1073-1097
|
|
|
13.
|
|
10 p, 1.3 MB |
Analysis of the effectiveness of second oral glucose-lowering therapy in routine clinical practice from the mediterranean area : A retrospective cohort study
/
Vlacho, Bogdan (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ;
Mundet-Tudurí, Xavier (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Mata-Cases, M. (Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas) ;
Vallès-Callol, J.A. (Institut Universitari d'Investigació en Atenció Primària Jordi Gol) ;
Real, J. (Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas) ;
Farre, Magi (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Cos Claramunt, Francesc Xavier (Institut Universitari d'Investigació en Atenció Primària Jordi Gol) ;
Khunti, K. (Diabetes Research Centre. University of Leicester) ;
Mauricio Puente, Dídac (Institut d'Investigació Biomèdica Sant Pau) ;
Franch-Nadal, J. (Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas) ;
Universitat Autònoma de Barcelona
Aim: To compare the changes in HbA1c, the effect on body weight or both combined after the addition of a DPP-4i, SGLT-2i, or sulfonylureas (SU) to metformin in real-world condition. Methods: We used a primary care SIDIAP database. [...]
2021 - 10.1016/j.diabres.2020.108616
Diabetes research and clinical practice, Vol. 171 (january 2021) , p. 108616
|
|
|
14.
|
|
6 p, 716.7 KB |
How many people with type 2 diabetes fulfil the eligibility criteria for randomized, controlled trials of insulin glargine 300 U/mL in a real-world setting?
/
Mauricio Puente, Dídac (Institut d'Investigació Biomèdica Sant Pau) ;
Westerbacka, J. (Sanofi) ;
Nicholls, C. (Sanofi) ;
Wu, Jasmanda (Sanofi) ;
Gupta, R. (Accenture) ;
Eliasson, B. (Department of Medicine. University of Gothenburg. Sahlgrenska University Hospital)
Randomized controlled trial (RCT) populations often do not reflect those typically seen in clinical practice. This retrospective, observational cohort study analysed the real-world data of people with type 2 diabetes (T2DM) prescribed basal insulin analogues from electronic medical records (EMRs) in the Explorys database, which includes data from 39 integrated healthcare systems in the United States, to determine how representative selected RCTs investigating insulin glargine 300 U/mL (Gla-300) are of T2DM populations in a real-world setting. [...]
2021 - 10.1111/dom.14264
Diabetes, Obesity and Metabolism, Vol. 23 Núm. 3 (march 2021) , p. 838-843
|
|
|
15.
|
|
16 p, 628.4 KB |
Glycaemic Control with Insulin Glargine 300 U/mL in Individuals with Type 2 Diabetes and Chronic Kidney Disease : A REALI European Pooled Data Analysis
/
Mauricio Puente, Dídac (Institut d'Investigació Biomèdica Sant Pau) ;
Gourdy, P. (Institute of Metabolic and Cardiovascular Diseases. UMR1048 INSERM/UPS. Toulouse University) ;
Bonadonna, Riccardo C (Department of Medicine and Surgery. University of Parma) ;
Freemantle, N. (Institute of Clinical Trials and Methodology. University College London) ;
Bigot, Gregory (IVIDATA) ;
Mauquoi, C. (IDDI) ;
Ciocca, A. (General Medicines. Sanofi) ;
Bonnemaire, Mireille (General Medicines. Sanofi) ;
Müller-Wieland, D. (Department of Medicine I. University Hospital Aachen)
Introduction: Management of type 2 diabetes mellitus (T2DM) in patients with chronic kidney disease is complex. Using the REALI European pooled database, we determined the impact of baseline renal function on the effectiveness and safety of insulin glargine 300 U/mL (Gla-300) initiated in adults with inadequately controlled T2DM. [...]
2021 - 10.1007/s13300-021-01031-z
Diabetes Therapy, Vol. 12 Núm. 4 (april 2021) , p. 1159-1174
|
|
|
16.
|
|
8 p, 1.3 MB |
Evaluation of clinical and antidiabetic treatment characteristics of different sub-groups of patients with type 2 diabetes : Data from a Mediterranean population database
/
Mata-Cases, M. (Institut Català de la Salut. ABS La Mina (Barcelona)) ;
Franch-Nadal, Josep (Institut Català de la Salut. Centre d'Atenció Primària Raval Sud (Barcelona, Catalunya)) ;
Real, J. (Universitat Internacional de Catalunya. Epidemiologia i Salut Pública) ;
Vlacho, Bogdan (Institut Universitari d'Investigació en Atenció Primària Jordi Gol) ;
Gómez-García, A. (Global Medical and Scientific Affairs. MSD Spain) ;
Mauricio Puente, Dídac (Institut d'Investigació Biomèdica Sant Pau)
Aims: To describe the characteristics and antidiabetic treatment among type 2 diabetes patients according to the clinical conditions prioritized in the Spanish 2020 RedGDPS (Primary Care Diabetes Study Groups Network) therapeutic algorithm: obesity, older than 75 years, chronic kidney disease, cardiovascular disease, and heart failure. [...]
2021 - 10.1016/j.pcd.2021.02.003
Primary Care Diabetes, Vol. 15 Núm. 3 (june 2021) , p. 588-595
|
|
|
17.
|
|
|
18.
|
|
|
19.
|
|
18 p, 506.2 KB |
Outstanding improvement of the advanced lipoprotein profile in subjects with new-onset type 1 diabetes mellitus after achieving optimal glycemic control
/
Castelblanco, Esmeralda (Institut Universitari d'Investigació en Atenció Primària Jordi Gol) ;
Hernández, Marta (Institut de Recerca Biomèdica de Lleida) ;
Ortega, Emilio (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Amigó, Núria (Institut d'Investigació Sanitària Pere Virgili) ;
Real, J. (Institut Universitari d'Investigació en Atenció Primària Jordi Gol) ;
Granado-Casas, Minerva (Institut d'Investigació Biomèdica Sant Pau) ;
Miñambres, Inka (Institut d'Investigació Biomèdica Sant Pau) ;
López, C. (Institut de Recerca Biomèdica de Lleida) ;
Lecube, Albert (Institut de Recerca Biomèdica de Lleida) ;
Bermúdez-López, Marcelino (Institut de Recerca Biomèdica de Lleida) ;
Alonso Pedrol, Núria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Julve i Gil, Josep (Institut d'Investigació Biomèdica Sant Pau) ;
Mauricio Puente, Dídac (Institut d'Investigació Biomèdica Sant Pau) ;
Universitat Autònoma de Barcelona
Aims: The impact of glycemic optimization on lipoprotein subfraction parameters in apparently normolipidemic subjects with new-onset type 1 diabetes mellitus (T1D) was examined. Methods: We evaluated the serum lipid and advanced lipoprotein profiles in twenty subjects at onset of T1D and twenty non-diabetic controls by laboratory methods and 1H NMR spectroscopy shortly after diabetes diagnosis (baseline), and after achieving optimal glycemic control (HbA1c ≤ 7. [...]
2021 - 10.1016/j.diabres.2021.109145
Diabetes research and clinical practice, Vol. 182 (december 2021) , p. 109145
|
|
|
20.
|
|
8 p, 689.8 KB |
Prenatal Betamethasone Exposure and its Impact on Pediatric Type 1 Diabetes Mellitus : A Preliminary Study in a Spanish Cohort
/
Perna-Barrull, David (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Murillo-Vallés, Marta (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Real, Nati (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Gómez Muñoz, Laia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Rodríguez-Fernández, Silvia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Bel, Joan (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Puig Domingo, Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Vives Pi, Marta (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Universitat Autònoma de Barcelona
Betamethasone, a glucocorticoid used to induce lung maturation when there is a risk of preterm delivery, can affect the immune system maturation and type 1 diabetes (T1D) incidence in the progeny. It has been described that prenatal betamethasone protects offspring from experimental T1D development. [...]
2022 - 10.1155/2022/6598600
Journal of Diabetes Research, Vol. 2022 (march 2022)
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
